Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: A clinical efficacy trial

Journal of Neuro-Oncology

Volumn 79, Issue 2, 2006, Pages 153-157

  Taliansky Aronov, A ^a   Bokstein, F ^b   Lavon, I ^a   Siegal, T ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anaplastic; Chemotherapy; Clinical trial; Oligodendroglioma; Temozolomide

Indexed keywords

LOMUSTINE; PROCARBAZINE; STEROID; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 1P; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LYMPHOCYTOPENIA; MALE; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; TREATMENT OUTCOME;

EID: 33748449264     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9020-1     Document Type: Article

References (12)

1. Soffietti R, Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 5: 295-306, 2004
2. van den Bent MJ, Kros JM, Heimans JJ, et al Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group Neurology 51: 1140-1145, 1998
3. Cairncross JG, Aggressive oligodendroglioma: A chemosensitive tumor. Recent Res Cancer Res 135: 127-133, 1994
4. van den Bent MJ, Taphoorn MJ, Brandes AA, et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525-2528, 2003
5. van den Bent MJ, Chinot O, Boogerd W, et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14: 599-602, 2003
6. Chinot OL, Honore S, Dufour H, et al Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455, 2001
7. Yung WK, Prados MD, Yaya-Tur R, et al Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771, 1999
8. Cairncross G, Seiferheld W, Shaw E, Jenkins R et al: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma: Initial report of RTOG 94-02. Ninths Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2004, Neuro-Oncology, 2004, p 371
9. van den Bent MJ, Diagnosis and management of oligodendroglioma. Semin Oncol 31: 645-652, 2004
10. Cairncross G, Macdonald D, Ludwin S, et al Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013-2021, 1994
11. Lebrun C, Fontaine D, Ramaioli A, et al Long-term outcome of oligodendrogliomas. Neurology 62: 1783-1787, 2004
12. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, et al High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma. J Neuro-Oncol 65: 127-134, 2003